GlassScriptPhysician profile
Angela R Verardo
NPI 1164783593
$37,566.25
in general payments reported to CMS, 2019-2025
26 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 75% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2022: $8,404 · 2023: $27K · 2024: $244 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $4,244 · Consulting Fee: $2,067 · Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,037.30 |
| Travel and Lodging | $4,244.01 |
| Consulting Fee | $2,066.78 |
| Food and Beverage | $1,711.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $24,059.23 | 2021-2025 | Voxzogo 1.2mg |
| Alexion Pharmaceuticals, INC. | $12,478.31 | 2021-2024 | Strensiq |
| Sanofi-Aventis U.S. LLC | $149.45 | 2023 | |
| Abbvie INC. | $124.00 | 2021-2023 | Lupron Depot |
| Novo Nordisk INC | $90.67 | 2022-2025 | Sogroya, Norditropin |
| Dexcom, INC. | $75.95 | 2022-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $70.71 | 2022-2023 | Baqsimi |
| Endo Pharmaceuticals INC. | $56.17 | 2022-2023 | Supprelin |
| Ipsen Biopharmaceuticals, INC | $44.50 | 2022 | |
| Tandem Diabetes Care, INC. | $38.53 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $36.23 | 2022 | |
| Kyowa Kirin, INC. | $33.92 | 2023 | Crysvita |
| Janssen Biotech, INC. | $31.23 | 2022-2023 | Simponi Aria, Remicade, Stelara |
| Tolmar, INC. | $31.03 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $28.99 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $27.63 | 2023 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $27.38 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $25.85 | 2021 | |
| 180 Medical, INC. | $25.17 | 2022 | |
| Abbott Laboratories | $23.12 | 2021 | |
| Pfizer INC. | $17.80 | 2023 | |
| Insulet Corporation | $16.39 | 2023 | Omnipod |
| Neurelis, INC. | $15.97 | 2023 | Valtoco |
| Arbor Pharmaceuticals, INC. | $13.65 | 2022 | |
| Zealand Pharma US, INC. | $13.27 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Verardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.